[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin,2021,71(3):209-249.
[2] Tan WL, Jain A, Takano A, et al. Novel therapeutic targets on the horizon for lung cancer [J].Lancet Oncol, 2016,17(8):e347-e362.
[3] Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors [J]. Cancer Cell,2020,37(4):443-455.
[4] Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial [J].Lancet Oncol,2019,20(12):1655-1669.
[5] Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small cell lung cancer with mut ated epidermal growth factor receptor: NEJ009 study [J]. J Clin Oncol, 2020, 38(2):115-123.
[6] Papadimitrakopoulou VA, Mok TS, Han JY, et al.Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis [J].Ann Oncol,2020,31(11):1536-1544.
[7] Liu Q, Luo Y, Li Z, et al. Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity [J]. Bioorg Med Chem,2021,36:116094.
[8] Tsubata Y, Watanabe K, Saito R, et al. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B) [J]. Int J Clin Oncol, 2022,27(1):112-120.
[9] Ninomaru T, Hata A, Kokan C, et al. Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs [J]. Thoracic Cancer,2021,12(6):746-7510.
[10] Yang JC, Camidge DR, Yang CT, et al. Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: amulticenter, open-label, phase 1 trial [J]. J Thorac Oncol, 2020, 15(12):1907-1918
[11] Wang Y, Yang N, Zhang Y, et al. Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cisC797S triple mutations by brigatinib and cetuximab combination therapy [J]. J Thorac Oncol, 2020, 15(8):1369-1375.
[12] Yun J, Lee SH, Kim SY, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-Met bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC [J]. Cancer Discov, 2020, 10(8):1194-1209.
[13] Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study [J]. Lancet Oncol, 2018,19(1):139-148.
[14] Li, BT,Smit EF, Goto Y,et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer [J]. N Engl J Med,2022,386(3): 241-251.
[15] Fang W, Zhao S, Liang Y, et al. Mutation variants and co-mutations as genomic modifiers of response to afatinib in HER2-mutant lung adenocarcinoma [J]. Oncologist, 2020, 25(3): e545-e554.
[16] Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study [J]. Lancet Oncol, 2020, 21(3):373-386.
[17] Markham A. Savolitinib: first approval [J].Drugs ,2021,81(14):1665-1670.
[18] Krawczyk P, Grenda A, Terlecka P, et al. Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement [J]. Sci Rep,2021,11(1):20939.
[19] Heigener DF, Reck M. Crizotinib [J]. Recent Results Cancer Res,2018,211:57-65.
[20] Krawczyk P, Grenda A, Terlecka P, et al. Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement [J].Sci Rep,2021,11(1):20939.
[21] Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation [J].N Engl J Med,2021,384(25):2371-2381.
[22] Ou SI, Jänne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of Adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1) [J]. J Clin Oncol,2022 ,15:JCO2102752.
[23] Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet Respir Med, 2021, 9(3):305-314.
[24] Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A Phase 3 Randomized Clinical Trial [J]. JAMA Oncol, 2021, 7(5): 709-717.
[25] Yang Y, Wang Z, Fang J, et al.Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous nsclc: a randomized, double-blind,phase 3 study ( oncology program by innovent anti-PD-1-11) [J]. J Thorac Oncol,2020,15 ( 10) : 1636-1646.
[26] Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase Ⅲ trials checkMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small cell lung cancer [J]. J Clin Oncol, 2021, 39(7): 723-733.
[27] Li F, Dong X. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial [J]. Thorac Cancer,2021,12(23): 3085-3087.
[28] Cheng Y, Zhang L, Hu J, et al. Pembrolizumab plus chemotherapy for Chinese patients with metastatic squamous NSCLC in KEYNOTE-407 [J]. JTO Clin Res Rep,2021,2(10):100225.
[29] Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-smallcell lung cancer [J]. J Clin Oncol, 2020, 38(14): 1505-1517.
[30] Awad MM, Gadgeel SM, Borghaei H, et al. Long-term overall survival from Keynote-021 cohort g: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC [J]. J Thorac Oncol, 2021, 16(1):162-168.
[31] Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-Line treatment of PD-L1-Selected patients with NSCLC [J]. N Engl J Med, 2020, 383(14): 1328-1339.
[32] Wang L, Peng Y, Zeng X, et al. Cost-Effectiveness analysis of cemiplimab versus chemotherapy as first-line treatment in advanced NSCLC with PD-L1 expression levels of at least 50 [J].Adv Ther, 2021,38(8):4354-4365.
[33] Moreno V, Garrido P, Papadopoulos KP, et al. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort [J]. Lung Cancer,2021, 155:151-155.
[34] Nishio M, Barlesi F, West H, et al. Atezolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer: Results from the randomized phase III IMpower132 trial [J]. J Thorac Oncol, 2021,16(4):653-664.
[35] Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2021, 22(2): 198-211.
[36] Jiang C, Zhang L, Xu X, et al. Engineering a smart agent for enhanced immunotherapy effect by simultaneously blocking PD-L1 and CTLA-4 [J]. Adv Sci,2021,8(20):e2102500.
[37] Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study [J]. Lancet Oncol,2022,23(6):781-792.
